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Abstract Metallothioneins (MTs) are a class of ubiqui-
tously occurring low molecular mass, cysteine- and metal-
rich proteins containing sulfur-based metal clusters formed
with Zn(II), Cd(II), and Cu(I) ions. In mammals, four
distinct MT isoforms designated MT-1 through MT-4 exist.
The first discovered MT-1/MT-2 are widely expressed
isoforms, whose biosynthesis is inducible by a wide range
of stimuli, including metals, drugs, and inflammatory
mediators. In contrast, MT-3 and MT-4 are noninducible
proteins, with their expression primarily confined to the
central nervous system and certain squamous epithelia,
respectively. MT-1 through MT-3 have been reported to be
secreted, suggesting that they may play different biological
roles in the intracellular and extracellular space. Recent
reports established that these isoforms play an important
protective role in brain injury and metal-linked
neurodegenerative diseases. In the postgenomic era, it is
becoming increasingly clear that MTs fulfill multiple
functions, including the involvement in zinc and copper
homeostasis, protection against heavy metal toxicity, and
oxidative damage. All mammalian MTs are monomeric
proteins, containing two metal–thiolate clusters. In this
review, after a brief summary of the historical milestones
of the MT-1/MT-2 research, the recent advances in the
structure, chemistry, and biological function of MT-3 and
MT-4 are discussed.
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Introduction
In mammals, four distinct metallothionein (MT) isoforms
designated MT-1 through MT-4 exist. The first MT, later
found to be composed of the MT-1 and MT-2 isoforms,
was discovered more than 50 years ago by Margoshes and
Vallee [1] followed by the discovery of MT-3 [2] and
MT-4 [3] at the beginning of 1990s. The most predominant
isoforms MT-1/MT-2 are expressed in almost all tissues
and their biosynthesis is inducible by a variety of stress
conditions and compounds, including glucocorticoids,
cytokines, reactive oxygen species (ROS), and metal ions
[4]. In contrast, MT-3 and MT-4 are relatively unrespon-
sive to these inducers and their expression is primarily
confined to the central nervous system (CNS) [5] and
cornified and stratified squamous epithelium [3], respec-
tively. Presently, there are a great number of reviews
covering different biological and structural aspects of MT
research and focusing predominantly on MT-1/MT-2
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[6–16]. In recent years the role of MTs in the brain, in
particular of the MT-3 isoform, has been the subject of
intense research. The biological studies on brain MTs are
reviewed in this special issue. In this contribution, we
briefly summarize the historical milestones of MT-1/MT-2
research till about 1990 and focus on the recent advances in
the structure, chemistry, and biological functions of MT-3
and MT-4.
Metallothionein-1/metallothionein-2: historical
highlights
As discussed by the late Bert L. Vallee [17] in his contri-
bution to the first MT meeting, the discovery of MT has
been closely linked with the search for biological material
containing cadmium. The first report on the presence of this
metal in human organs, in particular kidney, was in the
Russian literature in 1941 [18]. In the mid-1950s the
translated article became available to Western scientists.
Upon screening for cadmium content in kidneys of a few
mammalian species, Margoshes and Vallee [1] identified
protein containing besides cadmium also a substantial
amount of zinc and lesser amounts of copper and iron after
fractionation of horse kidney cortex. The purification and
characterization of this material by Ka¨gi and Vallee [19]
revealed a low molecular mass 6–7-kDa metal- and cys-
teine-rich protein, named ‘‘metallothionein’’ (MT) to reflect
the extremely high thiolate sulfur and metal content, both of
the order of 10% (w/w). Further chromatographic separation
revealed the presence of two principal MTs, later designated
as MT-1 and MT-2, of 61–62 amino acids, of which 20 were
cysteines and none of which were aromatic amino acids.
Both MTs contained seven Zn(II) or Cd(II)/Zn(II) ions. The
subsequent protein sequencing showed a single polypeptide
chain with distinct clustering of the 20 cysteine residues into
Cys–X–Cys, Cys–Cys and Cys–X–X–Cys sequences,
where X stands for amino acids other than cysteine [20]
(Table 1). These unique features of the classical mamma-
lian MT-1 and MT-2 isoforms attracted the interest of sci-
entists from fields as different as biochemistry, molecular
biology, toxicology, and structural biology.
The toxicology studies were initiated by the finding that
MT was present in increased amounts in livers of rabbits
exposed to cadmium. It has been postulated that this
observation reflects the induced biosynthesis of this protein
by this metal and its role in metal detoxification [22]. This
initial assumption of MT-1/MT-2 induction by heavy
metals was later confirmed by the increased MT content in
liver, kidney, and intestines following the parenteral or
dietary administration of cadmium, copper, or zinc to
experimental animals [23]. In the years since this publi-
cation, a large number of articles on the role of MT-1/MT-
2 in metal toxicity have been published and similar con-
clusions have been drawn. However, the real advances
were the observations that mice that cannot synthesize any
MT are sensitive to cadmium toxicity, whereas mice that
express excess amounts of any MT are resistant to this
metal [24–26]. It has been demonstrated, moreover, that
selection for cadmium resistance with mammalian cells
always results in up to 80-fold increase of the entire MT
locus [27]. These observations reflected the original dis-
covery of cadmium-containing MT in horse kidney [1].
Even though cases of cadmium toxicity are known, they
are rare and exclusively caused by man. Therefore, it has
been suggested that even though a characteristic phenotype
of cells and mice with altered expression of MTs is the
sensitivity to cadmium toxicity, it seems unlikely that the
evolutionary conservation of these ubiquitous, inducible
genes in most organisms is driven by the ability of MTs to
detoxify cadmium [28]. Thus, the current notion is that
cadmium detoxification is a property of MTs rather than its
evolutionary function [29].
Molecular biology studies on MTs aimed at the under-
standing of the gene structure, function, and regulation.
The genes for human and mouse MT-1/MT-2 have been
most extensively studied [30–33]. Whereas four MT genes
are present in the mouse genome, in human a significant
genetic polymorphism exists. The human MT genes are
located on band 13 of the long arm of chromosome 16 and
are encoded by a multigene cluster of tightly linked genes.
There are at least seven functional MT-1 genes and a single
gene encoding the other MT isoforms MT-2 (MT-2A),
MT-3, and MT-4 [13]. A number of other MT or MT-like
genes and pseudogenes with significant homology to
functional MT genes exist within the human genome, but
their functionality is unknown. The MT genes encode for
two-domain proteins. The three exons composing the
Table 1 Alignment of amino acid sequences of the four human metallothionein (MT) isoforms using ClustalW
The conserved cysteine residues are highlighted. The numbering is that of the human MT-3 sequence. Generated with SeaView [21]
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human MT genes sequentially encode for the N-terminal
region of the b-domain (exon 1), the rest of the b-domain
(from residue 11 or 12; exon 2), and all of the a-domain
(from residue 31 or 32; exon 3). Exons 2 and 3 are spliced
at the junction of codons for the Lys/Lys or Arg/Lys res-
idues in the interdomain region. The promoter regions of
MT-1 and MT-2 genes contain several metal-responsive
elements (MREs) and glucocorticoid-responsive elements
as well as elements involved in basal level transcription.
The MT-1/MT-2 expression is also regulated by oxidative
stress by antioxidant responsive elements or by MREs that
are also responsive to oxidants. Metal-regulatory tran-
scription factor 1 (MTF-1), which is essential for basal
expression of MT-1/MT-2 and induction by zinc, binds to
promoter proximal MREs. MTF-1 binds to MREs through
its six C2H2 zinc fingers [34]. Although similar MREs
were also identified in the MT-3 gene, there were unre-
sponsive to zinc [35]. The DNA sequences responsible for
cell-specific regulation of MT-3 and MT-4 genes are cur-
rently unknown. The regulation of tissue-specific MT-3
gene expression in humans does not appear to involve a
repressor. Thus, other mechanisms such as chromatin
organization and epigenetic modifications may account for
the presence or absence of MT-3 transcription.
In early biochemical studies the biological role of MT-1/
MT-2 was sought. As the major zinc-binding proteins in
the cell, it has long been hypothesized that MTs can
potentially modulate many important biological processes
that involve zinc-requiring enzymes. Their involvement
can either be direct, via interaction with inactive apoen-
zymes, or indirect, by regulation of available Zn(II) in the
cell. The first demonstration that several zinc-requiring
apoenzymes can be reactivated by the transfer of Zn(II)
from Zn7MTs in vitro was 30 years ago [36]. Evidence that
apoMT, or thionein, readily removes Zn(II) from zinc-
finger transcription factors such as Sp1 and Xenopus laevis
TFIIIA in vitro, eliminating their DNA binding compe-
tence, has also been provided [37, 38]. The in vitro dem-
onstration that MTs are extraordinarily efficient scavengers
of free hydroxyl radicals formed during various forms of
oxidative stress suggested that these proteins may be a part
of such a protective system [39]. The primary targets of the
free-radical attack in MTs are thiolate groups of the metal–
thiolate clusters, which may be repaired in the cell by
reduced glutathione. Following this discovery, evidence
supporting such a physiological role of MTs in the cellular
defense system against oxidative stress and their induced
biosynthesis under these conditions was provided [40]. In
the postgenomic era it became clear that MTs can have
multiple biological functions.
In view of the high cysteine and metal content, the
structural investigations of MT-1/MT-2 were highly chal-
lenging. Since most of these studies were conducted before
1990, no recombinant protein expression systems were
available. The native MTs, as isolated from livers of
experimental animals, contained either Zn(II) or both
Zn(II) and Cd(II) ions. To examine the geometry and the
organization of metal binding sites, the native metal ions
were replaced by paramagnetic Co(II) or by the NMR-
active 113Cd isotope (I = 1/2). The optical and magneto-
optical (magnetic circular dichroism) studies of Co7MT
provided evidence for a tetrahedral-type of geometry of all
metal binding sites and their coordination by cysteine
thiolates [41]. Convincing evidence for the two-cluster
arrangement of the seven divalent metal ions in MT, i.e.,
for a three-metal and a four-metal cluster, has been pro-
vided by homonuclear 113Cd NMR decoupling studies of
113Cd7MT. In these studies, the Cd(II) coordination by both
terminal and bridging thiolate ligands was inferred from
the chemical shift position of the 113Cd resonances [42].
The observation of an antiferromagnetic coupling between
metal centers in electron spin resonance and magnetic
susceptibility measurements of Co7MT lend further support
for a cluster structure in MTs [43]. Through enzymatic
cleavage of Cd7MT and the
113Cd NMR characterization of
the Cd4-containing peptide, the indication for a two-
domain structure, each domain encompassing a metal-
thiolate cluster, was obtained [44]. The mechanism of
metal binding to apoMT-2 was studied by 1H NMR and
magnetic susceptibility measurements of the paramagnetic
Co(II) metalloform of the protein at room temperature. The
results revealed a detailed binding scheme in which both
metal–thiolate clusters in Co7MT-2 were formed in a
noncooperative manner [45]. However, in similar studies
using Cd(II), a specific cooperative binding to the a-
domain followed by the b-domain was revealed by circular
dichroism, magnetic circular dichroism, and 113Cd NMR
measurements [46, 47]. The substantially different metal
sizes of Cd(II) and Co(II), the latter being closely similar to
that of Zn(II), thiolate affinities, and the corresponding
bond lengths may account for the differences in the path-
way of cluster formation.
Since early attempts to crystallize MT-1/MT-2 failed in
a number of crystallography groups, a new solution NMR
method for the 3D structure determination, developed by
Kurt Wu¨thrich and coworkers in Zurich, was applied. The
first structural studies of Wu¨thrich’s group were conducted
on Cd7MT-2 from rabbit liver. However, the structure
elucidation by NMR measurements turned out to be more
difficult than expected because of the heterogeneity of
native protein, the absence of aromatics, leading to very
poor chemical shift dispersion, and the presence of Cd–Cys
coordinative bonds in the clusters which could not be
analyzed with nuclear Overhasuer effects. Crucial to the
structure elucidation was the preparation of structurally
homogeneous 113Cd7MT-2 samples, generated through the
J Biol Inorg Chem (2011) 16:1067–1078 1069
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method of metal reconstitution, and the development of
heteronuclear 1H–113Cd correlation experiments enabling
the cadmium–cysteine topology of the clusters in the rabbit
protein to be unraveled [48].
At about the time of the publication of the cluster
topology in rabbit 113Cd7MT-2, the crystal structure of
native rat Cd5,Zn2MT-2 was reported [49]. However, the
sequence-specific metal-cysteine coordinative bonds in the
crystal structure of the rat protein were substantially dif-
ferent from those found by NMR measurements for the
rabbit protein. Given the amount of this covalent connec-
tivity information, it was quite clear that this discrepancy
between the two sets of results was not something that
could be explained easily. Among others, the most likely
reasons considered by the scientific community were (1)
the NMR and crystallography results might both be correct
as differences in the respective primary structures exist,
i.e., the rat protein shows ten substitutions of non-cysteine
amino acids, (2) the structural differences were caused by
the metal reconstitution of the rabbit protein, and (3) the
results obtained using the newly developed NMR technique
are presumably incorrect. It is hard to imagine a less
desirable event at the early stage in the development of the
methodology for NMR structure determination of proteins
than that the NMR method should produce a high-profile
mistake. Also the structure of 113Cd7MT was one of the
first protein structures determined by NMR measurements,
and it was the first structure of a metalloprotein to be
determined. In an effort to resolve the discrepancy, NMR
studies aiming at the cluster topology in metal-reconsti-
tuted rat 113Cd7MT-2 and native rat
113Cd5,Zn2MT-2,
generated by the administration of 113Cd(II) salt to exper-
imental animals similarly to samples used in crystalliza-
tion, were undertaken [50]. The NMR data obtained for the
rat protein confirmed the cluster topology seen already with
the rabbit protein (Fig. 1). Subsequently the NMR struc-
tures of 113Cd7MT-2 from rat and rabbit livers were com-
pleted [51, 52] and those of human 113Cd7MT-2, and, for
comparison, native Zn7MT-2 were also determined
[53, 54]. The NMR structures of these three homologous
MTs are virtually identical, and later the crystal structure of
rat Cd5,Zn2MT-2 was redetermined and found to coincide
very closely with the NMR structure (Fig. 2) [55, 56].
The determination of the structure of mammalian and
later also of the crustacean and echinoderm MTs estab-
lished the presence of trinuclear and tetranuclear thiolate
clusters with divalent metal ions as the characteristic
structural motif. These structural studies led to the notion
about this class of proteins which include the exclusive
metal coordination by cysteines, the absence of aromatic
amino acids (with rare exceptions) and secondary structure.
However, in recent years the biochemical characterization
of bacterial and plant MTs, which differ considerably from
mammalian proteins, revealed that besides high cysteine
content, also aromatic amino acids, including histidine, are
present. Furthermore, structural studies on these MTs
revealed that apart from the trinuclear and tetranuclear
clusters, also mononuclear and binuclear metal binding
sites with divalent metal ions occur. In addition, in these
structures a well-defined protein fold and, in some instan-
ces, metal coordination by both cysteine and histidine
residues are encountered. The structural and functional
properties of bacterial and plant MTs are reviewed in this
special issue.
Metallothionein-3
Biological properties of metallothionein-3
In the human brain the MT-1/MT-2 and MT-3 isoforms
occur [9]. The most distinctive biological property of MT-3
is its extracellular growth inhibitory activity in neuronal
primary cultures, which led to its discovery [5]. Thus, MT-3,
but not MT-1/MT-2 antagonizes the ability of Alzheimer
disease brain extract to stimulate survival and neuritic
Fig. 1 Structure of the two
metal–thiolate clusters with
divalent metal ions (gray
spheres) in mammalian
MII7MT-2. The sulfur atoms
(yellow spheres) of cysteine
thiolates are labeled with the
cysteine residue number
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sprouting of cultured neurons [5, 57]. The observation that
constitutive expression of MT-3 but not MT-1 inhibited the
growth of cultured kidney cells under zinc-deficient con-
ditions supports distinct functions of both isoforms [58].
The discovered bioactivity led to the hypothesis that MT-3
may be involved in pathogenic processes leading to
Alzheimer disease. Independent studies supporting its role
in Alzheimer disease showed that MT-3 but not MT-1/
MT-2 protects neuronal cells from the toxic effect of
amyloid-b (Ab) peptide Ab1–40 [59]. However, these two
effects are functionally unrelated (see below).
That MT-3 displays biological properties not observed
for MT-1/MT-2 is clearly documented by in vivo studies in
which mice overexpressing MT-3 in most organs died as a
result of pancreatic atrophy, whereas expression of similar
amounts of MT-1 had no effect [60]. Although the reason
for MT-3 toxicity is unknown, these results provide bio-
logical evidence that the MT isoforms have different
functional properties. Other in vivo studies supporting this
conclusion showed that in a mouse model of brain injury,
exogenously administered MT-3, in contrast to human
MT-2, does not affect inflammation, oxidative stress, and
apoptosis [61]. The latter results highlight specific and
divergent roles of exogenous MT-3 when compared with
the MT-1/MT-2 isoforms.
Numerous studies investigated the localization of MT-1/
MT-2 and MT-3 in the CNS. MT-1 and MT-2 are present
throughout the brain and spinal cord, with the astrocytes
being the main cell type expressing both isoforms. In
contrast, MT-3, the isoform predominantly expressed in the
CNS [5], is localized in both neurons and astrocytes [10,
62, 63], where it appears to play an important role in the
homeostasis of copper and zinc [9]. The MT-1/MT-2 and
MT-3 isoforms have been reported to be secreted, sug-
gesting that they may play different biological roles in the
intracellular and extracellular space [64–66]. Previously,
the involvement of the receptor megalin in the renal uptake
of MT-1/MT-2 was described [67]. The same receptor also
mediates the transport of MT-1/MT-2 into neurons fol-
lowing brain injury [66]. Presently, no information on
whether the megalin receptor also mediates the transport of
MT-3 is available.
MT-3 is present in several brain regions at different
concentrations, being particularly concentrated in presyn-
aptic terminals of zinc-enriched neurons of cerebral cortex
and hippocampus. Zinc-enriched neurons belong to a sub-
set of glutamatergic neurons and as such contain presyn-
aptic zinc vesicles in which 10–15% of the total Zn(II) in
the brain is present. The colocalization of MT-3 and zinc
vesicles in zinc-enriched neurons led to the suggestion that
Fig. 2 The three-dimensional
X-ray crystal structure of rat
Zn2Cd5MT-2 (top) [55] and the
NMR solution structure of the
a-domain and b-domain of rat
113Cd7MT-2 (bottom) [51]. The
Cd(II) and Zn(II) ions are
shown as light-orange spheres
and blue spheres, respectively,
connected to the protein
backbone by cysteine thiolate
ligands. The models were
generated with PyMOL using
the Protein Data Bank
coordinates of 4MT2, 1MRT,
and 2MRT
J Biol Inorg Chem (2011) 16:1067–1078 1071
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the protein may contribute to the utilization of Zn(II) as a
neuromodulator [68]. Studies of Zn7MT-3 and zinc trans-
porter 3 knockout mice revealed that zinc transporter 3, a
transporter that concentrates Zn(II) in presynaptic vesicles,
and MT-3 function in the same pathway [69]. From these
studies an important role for MT-3 in the recycling of
Zn(II) was suggested [70]. The demonstration of the direct
interaction of Zn7MT-3 with Rab3A, a small GTPase
involved in the regulation of the synaptic vesicle cycle,
supports this role [71]. The immunochemical identification
of MT-3 as a component of a brain multiprotein complex
with heat shock protein 84 and creatine kinase [72] sug-
gests that MT-3 may have additional intracellular functions
that remain to be elucidated. Recently, the specific and
reversible binding of one extra Zn(II) to Zn7MT-3
(Kapp *100 lM), forming Zn8MT-3, was reported [73].
Since during synaptic signaling the free Zn(II) concentra-
tion can reach up to 300 lM [74], a reversible switch
between the Zn7MT-3 and Zn8MT-3 forms may play a role
as a zinc buffer or in an interaction with a binding part-
ner(s). The analytical results of the latter study suggest that
the reported coexistence of MT-3 species in solution with a
metal distribution between five to nine M(II) per protein
(M is Zn, Cd), detected by electrospray ionization (ESI)
mass spectrometry (MS) upon binding of seven M(II)
equivalents to apoMT-3, seems to reflect the reconstitution
and ionization conditions used [75].
MT-3, like other MTs [39, 40, 76, 77], efficiently scav-
enges ROS. Thus, exogenous MT-3 prevents neurite
extension and the death of differentiated cortical neurons
caused by exposure to high oxygen concentrations, owing to
its more efficient scavenging of free hydroxyl radicals than
the same concentration of Zn7MT-1/MT-2 [64]. However,
studies of MT-3-null mice following damage caused by a
focal cryolesion onto the cortex showed that, in contrast to
MT-1/MT-2, MT-3 is unlikely to be a significant factor for
controlling the inflammatory response, oxidative stress, and
apoptosis after significant brain damage, but it may influ-
ence neuronal regeneration [78]. The in vitro reactions of
S-nitrosothiols and H2O2 with Zn7MT-1/MT-2 and
Zn7MT-3 revealed that whereas Zn7MT-3 was significantly
more reactive than Zn7MT-1/MT-2 toward S-nitrosothiols,
the reactivity of all three isoforms toward H2O2 was com-
parable. The increased reactivity of Zn7MT-3 with free NO
and S-nitrosothiols led to the proposal that Zn7MT-3 may
specifically convert NO signals to zinc signals [79]. The
metal-induced aggregation of Ab and accompanied oxida-
tive stress contribute to the progression of Alzheimer dis-
ease (see below). In vitro studies showed that in contrast to
amorphous aggregates of Ab formed upon Zn(II) addition,
the Zn(II) release from Zn7MT-3 upon a slow cysteine
oxidation by H2O2 induces fibrillar-type Ab aggregates,
thereby modulating its morphology. Thus, the protein may
protect cells not only by its capacity for ROS scavenging,
but also through Zn(II) release and subsequent binding to
Ab [80]. Recently, in view of the finding that MT-3 regu-
lates lysosomal functions, possible roles of labile zinc and
Zn7MT-3 in oxidative-stress-induced lysosomal dysfunc-
tion, cell death, and autophagy in neurons and astrocytes
have been described [81]. Given the accumulating evidence
that lysosomes play key roles in many neurological dis-
eases, the role of labile zinc and Zn7MT-3 in lysosomal
function warrants further study.
As discussed above, the regulation of the basal MT-3
expression is poorly understood. Nevertheless, in recent
years overexpression of MT-3 in certain cancer types
including prostate [82] and breast [83] has been described.
Since the MT-3 gene was identified as hypoxia-inducible in
several human tissues [84], the overexpression of MT-3
observed in several cancers presumably reflects the hyp-
oxic conditions, due to insufficient vascularization of the
fast-proliferating cancer tissue. MT-3, similarly to MT-1/
MT-2, may confer cellular resistance in platinum-based
chemotherapy in these cell types [85]. However, kinetics of
the reaction of cisplatin with Zn7MT-3 and Zn7MT-2
revealed a substantially higher reactivity of cisplatin
toward Zn7MT-3 than Zn7MT-2 [86].
Structure of metallothionein-3 with divalent metal ions
The distinct biological activity of MT-3 has been linked to
the structural differences between MT-1/MT-2 and MT-3.
As the structure of MTs is determined by the interplay
between the polypeptide chain and metal ions, the differ-
ences in amino acid sequences ought to be responsible for
the bioactivity. Compared with the amino acid sequences
of mammalian MT-1/MT-2 (Table 1), the MT-3 sequence
shows two inserts, an acidic hexapeptide in the C-terminal
region and a threonine in position 5 in the N-terminal
region followed by a conserved C6PCP9 motif. Structural
information on the metal–thiolate clusters in MII7MT-3 was
forthcoming from spectroscopic investigations of the
recombinant protein and chemically synthesized single
protein domains. The studies revealed the presence of two
mutually interacting protein domains, with each domain
encompassing a metal–thiolate cluster [87–90]. A three-
metal cluster is located in the N-terminal b-domain (resi-
dues 1–31) and a four-metal cluster is located in the
C-terminal a-domain (residues 32–68) of MII7MT-3 [88,
89], a metal organization found also in MII7MT-1/MT-2
(Fig. 2). From 113Cd NMR studies of human 113Cd7MT-3,
evidence for unprecedented dynamic processes within the
metal–thiolate clusters was obtained [90]. From significant
broadening of all 113Cd resonances and the very low and
temperature-independent intensity of the Cd3Cys9 cluster
resonances, the presence of dynamic processes acting on
1072 J Biol Inorg Chem (2011) 16:1067–1078
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two different 113Cd NMR timescales was suggested: (1)
fast exchange between conformational cluster substates
giving rise to broad, weight-averaged resonances and (2)
additional very slow exchange processes between config-
urational cluster substates in the b-domain. The changes in
conformational substates may be visualized as minor
dynamic fluctuations of the metal coordination environ-
ment and those of the configurational substates as major
structural alterations brought about by temporarily break-
ing and reforming of the metal-thiolate bonds [90]. The
existence of interchanging configurational cluster substates
of comparable stability was demonstrated for inorganic
adamantane-like metal–thiolate clusters with the general
formula [M4(SPh)10]
2- (M is Cd(II), Zn(II), Co(II), and
Fe(II)] [91]. Studies toward obtaining the 3D NMR struc-
ture of mouse and human Cd7MT-3 have also been
undertaken [92, 93]. However, because of dynamic pro-
cesses in the b-domain of Cd7MT-3, only the 3D structure
of the C-terminal a-domain (residues 32–68), containing an
adamantane-like Cd4Cys11 cluster, could be determined by
NMR measurements. The structure of this domain reveals a
peptide fold and cluster organization very similar to that
found in mammalian Cd7MT-1/MT-2, with the exception
of an extended flexible loop encompassing the acidic
hexapeptide insert (Fig. 3).
To account for slow dynamic events centered at the
three-metal cluster of MT-3, a partial unfolding of the b-
domain, whose kinetics could be determined by the cis/
trans interconversion of Cys-Pro amide bonds in the
C6PCP9 motif, has been suggested [94]. Support for this
model came from extended X-ray absorption fine structure
(EXAFS) studies of Zn7MT-3 and its single Zn3b-domain
where, besides evidence for the tetrahedral tetrathiolate
Zn(II) coordination, also indication of an unusual structure
of the three-metal cluster was obtained. In both Zn3b-
domains a ZnZn backscattering at about 3.28 A˚ was
detected (Fig. 4) [87]. Since this distance is inconsistent
with the cyclohexane-like Zn3Cys9 cluster structure present
in the b-domain of mammalian MT-2, where a ZnZn
distance of about 3.8 A˚ exists [56], it may reflect a pre-
dominant population of one cluster configuration under the
conditions used (at 77 K).
Additional insights into the dynamics of the b-domain of
Cd7MT-3 were provided by molecular dynamics simula-
tions. The simulation of the partial unfolding supported the
proposed role of cis/trans interconversion of Cys-Pro
amide bonds in the folding/unfolding process of the b-
domain of Cd7MT-3 [95]. In other molecular dynamics
simulations, a correlation between the number of backbone
amide hydrogen bonds to metal coordinated cysteines,
NH–Sc hydrogen bonds, in mammalian Cd7MTs has been
proposed to represent a controlling factor regulating the
metal-thiolate cluster dynamics [96].
The C6PCP9 motif was the first segment found to be
important for the extracellular growth inhibitory activity of
Zn7MT-3 [57, 94]. Mutational studies on biologically
inactive Zn7MT-1 revealed that besides the introduced
C6PCP9 motif, also the unique Thr5 is required for the
bioactivity and structure dynamics [97]. Further insights
into the structural features underlying the bioactivity of
Zn7MT-3 came from a number of mutational studies which
revealed that other amino acids in the b-domain along with
domain–domain interactions, mediated partly through the
acidic hexapeptide insert in the a-domain, are important
(reviewed in [98]). Thus, although the mechanisms
underlining these biological effects remain to be eluci-
dated, the results obtained so far suggest that the structure
of the b-domain of Zn7MT-3 is subjected to a fine-tuning.
Taken together, the findings of the structural and muta-
tional studies led to the conclusion that both the specific
structural features and the structure dynamics are necessary
prerequisites for the extracellular biological activity of
Fig. 3 The NMR solution structure of the a-domain of human
113Cd7MT-3 [93]. The Cd(II) ions are shown as light-orange spheres
connected to the protein backbone by cysteine thiolate ligands. The
model was generated with PyMOL using the Protein Data Bank
coordinates of 2F5H
Fig. 4 Structural model of the Zn3(Cys)9 cluster in Zn7MT-3 (right)
and in comparison with the cyclohexane-like Zn3(Cys)9 cluster
present in Zn7MT-2 (left). Metal ions are shown as blue spheres
connected to cysteine sulfur ligands (yellow). EXAFS: extended
X-ray absorption fine structure. (Adapted with permission from [87])
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Zn7MT-3 [94, 97, 98]. The bioactivity in neuronal assays
has been established for Cu(I)4Zn3–4MT-3 isolated from
human [2] and bovine [99] brains and for recombinant
human Zn7MT-3 [98, 100]. However, comparative bio-
logical studies on well-defined metalloforms are currently
lacking. Recently, two reviews focusing on various aspects
of the structure and biology of MT-3 have been published
[101, 102].
Structural features of Cu(I)-bound metallothionein-3
Whereas isolated mammalian MT-1 and MT-2 from livers
of various species usually contain seven Zn(II), MT-3
isolated from human and bovine brains contains four
Cu(I) and between three and four Zn(II). The isolated
Cu(I)4Zn3–4MT-3 is a monomeric protein stable in air.
EXAFS studies on Cu(I)4Zn3–4MT-3 revealed the presence
of two homometallic clusters, a Cu(I)4–thiolate cluster and
a Zn3–4–thiolate cluster [87]. The EXAFS data indicated
that in contrast to tetrahedrally coordinated Zn(II) ions,
Cu(I) ions are diagonally and/or trigonally coordinated by
two or three cysteine ligands [87]. This observation, also
seen for the Cu(I)–thiolate clusters in MT-1/MT-2, signi-
fies that there are different coordination geometries for the
binding of monovalent and divalent metal ions to MT-3.
Therefore, to accommodate metal–thiolate clusters with
different coordinating geometries, the structure should
possess a high degree of flexibility.
Detailed information on the interaction of Cu(I) with
MT-3 was forthcoming from spectroscopic studies of
Cu(I) binding to the metal-free a-domain and b-domain
and the full-length protein. The stepwise Cu(I) binding to
both individual MT-3 domains showed that two well-
defined Cu(I)–thiolate cluster forms are generated during
this process. In the case of the b-domain (residues 1–32;
Table 1), the successive formation of two cluster forms
involving all nine cysteine ligands was observed, i.e.,
Cu4S9 and Cu6S9 clusters [88]. Similar studies on the a-
domain (residues 32–68), containing 11 cysteine ligands,
resulted in the formation of a Cu4S8–9 cluster followed by a
Cu6S11 cluster [89]. In addition, the formation of the Cu4S9
cluster in both the single b-domain and full-length protein
was cooperative [88, 103]. The cooperative formation of a
stable folding intermediate containing a Cu4S9 cluster in
the b-domain has also been shown by ESI–MS [104]. The
major differences in the respective spectroscopic features
between the Cu(I)4 and Cu(I)6 cluster forms were observed
in the low-temperature Cu(I) luminescence spectra at 77 K
[88, 89, 103]. Whereas the Cu(I)6 cluster exhibited only a
single emission band at 600 nm, in the case of the Cu(I)4
clusters two emission bands at 420 and 610 nm were dis-
cerned. The presence of two emission bands in Cu(I)4
clusters has been correlated with short intranuclear CuCu
distances (less than 2.8 A˚), allowing metal–metal interac-
tions due to a d10–d10 orbital overlap. Accordingly, the
high-energy emission band has been assigned to a 3CC
(cluster-centered) origin and that at low energy to triplet
charge transfer [88, 89, 105]. The metal–metal interactions
may contribute to the stability of the Cu(I)4–thiolate cluster
to oxidation in air. This is supported by the observation that
the expansion of the metal core, generating a Cu(I)6–
thiolate cluster, results in increased CuCu distances and
susceptibility to oxidation [105]. Similarities between the
luminescence spectra of isolated Cu4,Zn3–4MT-3 and the
Cu(I)4–thiolate cluster in the single b-domain suggested the
presence of this cluster also in the isolated protein. Taken
together the data indicated that the b-domain of MT-3
shows clear preference for binding of Cu(I) over Zn(II)
ions.
The generation of a nativelike MT-3 structure through
direct Cu(I) and Zn(II) incorporation into the recombinant
apoprotein revealed monomeric Cu4,Zn4MT-3, in which,
besides the Cu(I)4 cluster in the b-domain, a Zn4 cluster in
the a-domain was present [103]. Whereas the Cu(I)4 cluster
in Cu4,Zn4MT-3 possesses the already mentioned stability
to air oxygen, the Zn4 cluster was found to be air-sensitive.
Its oxidation resulted in disulfide formation and the release
of one Zn(II), yielding Cu4,Zn3MT-3. This process could
be prevented or reversed under reducing conditions [106].
Roles of metallothionein-3 in metal-linked
neurodegenerative disorders
A predisposing risk factor associated with neurodegenera-
tive diseases is age. In the normal brain a high concen-
tration of essential transition metal ions such as zinc,
copper, and iron ions is present. Dysregulated metal
homeostasis, abnormal metal–protein interactions, and the
associated oxidative stress, protein misfolding, and aggre-
gation are critical common pathological hallmarks of the
progression of several metal-linked neurodegenerative
disorders [107, 108]. Insoluble protein deposits and dif-
fusible oligomers are composed of individual amyloido-
genic proteins or peptides such as the Ab peptides, a major
component of extracellular amyloid plaques in Alzheimer
disease, prion protein in prion deposits typical of Creutz-
feldt–Jakob disease, a-synuclein (a-Syn) in intracellular
Lewy bodies in Parkinson disease, superoxide dismutase
(SOD-1) aggregates in amyotrophic lateral sclerosis, and
Huntington inclusions in cases of Huntington disease. In
these neurodegenerative diseases, the expression of MT-3
has been found to be downregulated or altered [109–111]
and changes in normal homeostasis of essential transition
metals such as zinc and copper have been implicated as
possible etiological factors [108, 112]. In contrast to redox-
inert zinc, redox-active copper aberrantly bound to
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amyloidogenic proteins can react with molecular oxygen,
resulting in the production of ROS through Fenton and
Haber–Weiss reactions [113]. That MT-3 may play an
important role in the progression of these diseases has been
reviewed [111].
A protective role of extracellular Zn7MT-3 from Cu(II)
toxicity has been suggested on the basis of investigations of
its reactivity toward free Cu(II) ions [114]. The results
showed that Zn7MT-3 through Cu(II) reduction to Cu(I) by
thiolate ligands and binding to the protein, forming an air-
stable Cu(I)4Zn4MT-3 species, efficiently scavenges and
redox-silences the free Cu(II) ions. In this reaction, a
Cu(I)4–thiolate cluster is formed cooperatively in the b-
domain of the protein concomitant with two intramolecular
disulfide bonds and the release of three Zn(II) ions [114].
Since four Zn(II) ions remained bound, the presence of an
intact Zn4 cluster in the a-domain was suggested. The
formation of Cu(I)4Zn4MT-3 completely quenched the
ascorbate-driven and Cu(II)-catalyzed production of ROS
[114]. Taken together the findings indicate that two types
of air-stable Cu(I)4–thiolate clusters can be formed in the
more reactive b-domain of MT-3, i.e., a fully reduced
Cu(I)4S9 cluster and a Cu(I)4S5?x cluster. In the latter, by
analogy with inorganic model complexes, the participation
of a disulfide bridge sulfur (indicated by x) besides thiol-
ates in the Cu(I) coordination cannot be excluded.
Studies aimed at understanding the protective effect of
human Zn7MT-3 against Ab1–40 toxicity showed that the
protein can efficiently remove copper not only from soluble
Ab1–40–Cu(II) oligomers, but also from insoluble aggre-
gates. In this process, Cu(II) is reduced by protein thiolates,
forming the stable Cu(I)4Zn4MT-3 species described above
and the non-redox-active Ab1–40–Zn(II). This metal swap
completely quenches the ROS production mediated by
Cu(II) bound to Ab1–40 and occurs not only in vitro, but
also in human neuroblastoma cell culture, whereby the
toxic effect of Ab1–40–Cu(II) is abolished [115]. In recent
studies, the protective effect of human Zn7MT-2A against
Ab1-40–Cu(II) toxicity was also investigated and com-
pared with that of Zn7MT-3 [116]. In neuronal cell culture,
a similar protective effect has been shown. The results of
the reaction between Ab1-40–Cu(II) and Zn7MT-2A have
been discussed together with the chemical data on the fully
reduced Cu(I)10MT-2A and Cu(I)12MT-3 species, gener-
ated in the reaction of apoMT-2A or apoMT-3 with the
Cu(I)-DTT complex under strictly reducing conditions. It
has been suggested, moreover, that the increased affinity of
MT-2A for Cu(I) over MT-3 makes MT-2A a better pro-
tecting agent [116]. However, as the reduction of Cu(II) in
Ab1–40–Cu(II) to Cu(I) is accomplished by the thiolate
ligands of both MTs, the formation of fully reduced
Cu(I)MT-2A/MT-3 metalloforms in the oxidizing extra-
cellular environment is highly unlikely. That under these
conditions the reaction between Ab1-40–Cu(II) and
Zn7MT-2A also leads to Cu(I)4Zn4MT-2A, in which a
Cu(I)4–thiolate cluster and two disulfide bonds are present,
has been revealed (G. Meloni, C.L. Seeland, and M. Vasˇa´k,
unpublished). Note also that the implicated direct metal
swap between Cu(II), coordinated by nitrogen and oxygen
ligands in Ab1–40–Cu(II), and Zn(II), coordinated by thio-
late ligands in Zn7MT-2A, without preceding Cu(II)
reduction cannot occur. Consequently, the differences in
Cu(I) affinity for MTs are not essential for the protective
effect, but rather the long-term stability of partially oxi-
dized Cu(I),ZnMTs formed upon Cu(II) reduction and
removal from Ab1-40–Cu(II) in the oxidizing extracellular
space are essential. The ensuing redox cycling of copper in
oxygen-sensitive Cu(I),ZnMTs can change their properties
from antioxidant to prooxidant. In this context it may be
noted that although the MT-1/MT-2 isoforms have been
found to be significantly upregulated in regions of Ab
plaques in the Alzheimer disease brain [117–120], the
presence of substantial concentrations of Cu(II) in these
plaques (0.3 mM) has been shown [108, 121]. Clearly,
more studies regarding the stability of brain MTs formed in
the reaction between Zn7MTs and different concentrations
of Cu(II) to molecular oxygen are needed.
Besides Alzheimer disease, a protective effect of MT-3
has also been considered in other metal-linked neurode-
generative diseases such as Parkinson disease and prion
diseases [111]. Studies conducted on hemiparkinsonian rats
suggest that the free-radical scavenging potency, including
that of MT-3, is reduced in the Parkinson disease brain
[111]. In Parkinson disease, the fibrillation and aggregation
of a-Syn is a key process in the formation of intracellular
inclusions, Lewy bodies, in neurons of substantia nigra pars
compacta [122]. Aberrant tight binding of one Cu(II) to a-
Syn and associated oxidative stress appears to contribute to
the degeneration of dopaminergic neurons through the
abnormal aggregation of this protein [123–125]. In prion
diseases, transmitted by proteinaceous infective agents
(prions) [126], the transition from natively folded prion
protein (PrPC) to misfolded prion protein (PrPSc) is a crucial
pathogenic event [107, 127]. The mainly disordered part of
the PrPC structure can bind up to six Cu(II) ions [107]. Also,
in this case oxidative stress, associated with the copper-
catalyzed transformations of prion protein, plays an
important role in the disease progression. Recent in vitro
studies into the role of Zn7MT-3 in Parkinson disease and
prion diseases have shown that Zn7MT-3, through Cu(II)
removal from a-Syn and prion protein and the formation of
air-stable Cu(I)4Zn4MT-3 species, efficiently prevents the
deleterious redox activity of these proteins [128]. In view of
widely different Cu(II) binding motifs in Ab, a-Syn, and
prion proteins, a general protective role of Zn7MT-3 against
Cu(II) toxicity in the brain can be envisaged.
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Metallothionein-4
The last member of the mammalian MT gene family MT-4 is
located about 20 kb upstream from the 50 of the MT-3 gene
in both the mouse and the human genome [3]. MT-4 consists
of 62 amino acids, with an insert of glutamate in position 5
relative to the classical MT-1 and MT-2 proteins (Table 1).
Murine MT-4 messenger RNA appears to be present
exclusively in cornified and stratified squamous epithelia.
Many of these epithelia develop parakeratosis during zinc
deficiency in rats. Differentiation of stratified epithelium
involves movement of keratinocytes out of the basal, pro-
liferative layer into the overlaying region where synthesis of
unique cytoskeletal proteins begins. In situ hybridization
revealed intense labeling of MT-4 messenger RNA in the
differentiating spinous layer of cornified epithelia, whereas
MT-1 was expressed predominantly in the basal, prolifera-
tive layer. Thus, a switch in MT isoform synthesis occurs
during differentiation. The MT-4 derived from tongue epi-
thelium contained both zinc and copper (ratio 2.6:1) [3].
From molecular and cell biology studies, involvement of
MT-4 in regulating zinc metabolism during the differenti-
ation of stratified epithelia has been suggested [3]. Molec-
ular biology and expression profile studies of MT-4 in
mammalian maternal decidua [129] and during epithelia
development and physiology [3, 130] revealed that the MT-4
gene is subject to a strict developmental regulation.
The function of MT-4 in handling divalent Zn(II) or
monovalent Cu(I) metal ions has been inferred from its
structural properties. The organization, stability, and
assembly of divalent metal ions in mammalian MT-4 have
been investigated using the Cd(II) and Co(II) metalloforms
of the protein and have been compared with the well-
characterized mammalian Cd7MT-2 [131]. Both
113Cd
NMR studies of reconstituted 113Cd7MT-4 and spectro-
scopic characterization of Co7MT-4 revealed that, similarly
to the classical MT-1 and MT-2 proteins, the seven diva-
lent metal ions are organized into two independent
Cd4Cys11 and Cd3Cys9 clusters, with each metal ion tet-
rahedrally coordinated by terminal and l-bridging cysteine
ligands [131]. The cluster formation in Cd7MT-4 was
cooperative and sequential, with the Cd4Cys11 cluster in
the a-domain being formed first. In addition, the metal–
thiolate clusters in MT-4 appear more stable to demetal-
lation by EDTA than those of MT-1 [132]. The decreased
ligand substitution reactivity of EDTA observed with
Cd7MT-4 presumably reflects marked differences in the
cluster geometry in Cd7MT-4 compared with Cd7MT-1/
MT-2 [131].
Insights into the Cu(I) binding specificity of MT-4 have
been obtained from the characterization of metalloforms
upon heterologous expression of MT-4 and its individual
domains in Escherichia coli culture using zinc-, cadmium-,
or copper-supplemented media and their comparison with
the well-characterized metalloforms of MT-1 [133].
Spectroscopic and ESI–MS analyses of the metal compo-
sition of the purified full-length protein and the individual
a- and b-domains revealed that compared with MT-1, the
MT-4 isoform shows an increased preference for mono-
valent copper ions over divalent zinc or cadmium ions,
properties reflected in the formation of mixed MII
(M is Zn, Cd) and Cu(I) species [133]. On the basis of
these results and the in silico protein sequence analyses, it
has been concluded that MT-4 differentiated to a MT with
a ‘‘copper thionein’’ character rather than to a MT with a
‘‘zinc thionein’’ character. It has been suggested, moreover,
that the dissimilarities in non-cysteine residues between
MT-4 and MT-1 are responsible for the differences in
metal binding behavior. Furthermore, the diminished
Cd(II) binding ability of Cd4-aMT-4 versus Cd4-aMT-1
has been attributed to its high proline content, in agreement
with the association of Cys-Pro motifs to structural per-
turbations in MT-3 [97]. Overall, the structural studies
support the role of MT-4 in both zinc and copper metab-
olism in epithelia. Nevertheless, more work regarding the
3D structure of MT-4 and its physiological role are needed.
In more recent studies, the presence of about 14 and
3 mol of sulfide (S2-) ligands in recombinant full-length
CdMT-4 and CdMT-1, respectively, has been reported [134,
135]. This finding led to the reinterpretation of the all
assumed heterometallic Zn,Cd-bMT-4 species in the pre-
vious heterologous expression of MT-4 [133] as Cd-bMT-4
complexes that include sulfide ligands. However, although
in these studies convincing analytical evidence for the
presence of sulfide in these and other recombinant prepa-
rations of mammalian MTs was provided, in the analyses for
MT isoforms present in the cytosol of mammalian cells and
tissues by the combination of various analytical techniques,
including capillary electrophoresis (CE) inductively cou-
pled plasma MS and CE–ESI–MS, mass peaks of fully metal
occupied MT isoforms without sulfide have been reported
[136, 137]. Since in these studies MT isoforms containing
sulfide may have escaped detection owing to their substan-
tially increased molecular masses, more studies are needed
to clarify the presence of sulfide in mammalian MTs.
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